The investigational antiviral ensitrelvir promises to accelerate recovery from mild to moderate COVID-19. Investigators concluded that patients who received the investigational drug recovered from COVID-19 symptoms about 24 hours earlier than those in the control group. Additionally, participants in the ensiltrelvir group tested negative for SARS-CoV-2 about 29 hours earlier. The drug, developed by Shionogi…